 |
PDBsum entry 5frm
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Recombination
|
PDB id
|
|
|
|
5frm
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Hiv-1 integrase strand transfer inhibitors with reduced susceptibility to drug resistant mutant integrases.
|
 |
|
Authors
|
 |
X.Z.Zhao,
S.J.Smith,
D.P.Maskell,
M.Metifiot,
V.E.Pye,
K.Fesen,
C.Marchand,
Y.Pommier,
P.Cherepanov,
S.H.Hughes,
T.R.Burke.
|
 |
|
Ref.
|
 |
Acs Chem Biol, 2016,
11,
1074-1081.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
HIV integrase (IN) strand transfer inhibitors (INSTIs) are among the newest
anti-AIDS drugs; however, mutant forms of IN can confer resistance. We developed
noncytotoxic naphthyridine-containing INSTIs that retain low nanomolar IC50
values against HIV-1 variants harboring all of the major INSTI-resistant
mutations. We found by analyzing crystal structures of inhibitors bound to the
IN from the prototype foamy virus (PFV) that the most successful inhibitors show
striking mimicry of the bound viral DNA prior to 3'-processing and the bound
host DNA prior to strand transfer. Using this concept of "bi-substrate
mimicry," we developed a new broadly effective inhibitor that not only
mimics aspects of both the bound target and viral DNA but also more completely
fills the space they would normally occupy. Maximizing shape complementarity and
recapitulating structural components encompassing both of the IN DNA substrates
could serve as a guiding principle for the development of new INSTIs.
|
 |
|
|
|
|
 |